Dimensional Fund Advisors LP Buys 507,021 Shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO)

Dimensional Fund Advisors LP increased its stake in Allogene Therapeutics, Inc. (NASDAQ:ALLO) by 24.8% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,550,640 shares of the company’s stock after purchasing an additional 507,021 shares during the period. Dimensional Fund Advisors LP owned 1.22% of Allogene Therapeutics worth $5,944,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the company. Price T Rowe Associates Inc. MD raised its position in shares of Allogene Therapeutics by 76.2% during the first quarter. Price T Rowe Associates Inc. MD now owns 4,177,619 shares of the company’s stock worth $18,675,000 after acquiring an additional 1,806,147 shares during the last quarter. TD Asset Management Inc raised its holdings in Allogene Therapeutics by 82.7% during the 2nd quarter. TD Asset Management Inc now owns 799,340 shares of the company’s stock worth $1,862,000 after purchasing an additional 361,904 shares during the last quarter. Caxton Associates LP lifted its position in Allogene Therapeutics by 61.4% during the 4th quarter. Caxton Associates LP now owns 775,093 shares of the company’s stock valued at $2,488,000 after purchasing an additional 294,989 shares during the period. Bank of New York Mellon Corp lifted its position in Allogene Therapeutics by 20.6% during the 2nd quarter. Bank of New York Mellon Corp now owns 362,364 shares of the company’s stock valued at $844,000 after purchasing an additional 61,811 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. grew its position in shares of Allogene Therapeutics by 85.1% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 361,913 shares of the company’s stock worth $1,768,000 after buying an additional 166,433 shares during the period. Institutional investors and hedge funds own 83.63% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently weighed in on ALLO shares. Oppenheimer started coverage on shares of Allogene Therapeutics in a report on Thursday, August 8th. They issued an “outperform” rating and a $11.00 price objective on the stock. HC Wainwright reiterated a “buy” rating and issued a $9.00 price objective on shares of Allogene Therapeutics in a report on Thursday, August 15th. Truist Financial reiterated a “buy” rating and issued a $14.00 price target (down from $17.00) on shares of Allogene Therapeutics in a research report on Friday, August 9th. Citigroup lifted their target price on Allogene Therapeutics from $7.00 to $8.00 and gave the stock a “buy” rating in a report on Friday, August 9th. Finally, Canaccord Genuity Group lowered their target price on Allogene Therapeutics from $35.00 to $14.00 and set a “buy” rating for the company in a research note on Thursday, August 8th. Three equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $9.96.

Allogene Therapeutics Price Performance

Shares of NASDAQ ALLO opened at $2.74 on Wednesday. The firm has a market cap of $572.66 million, a price-to-earnings ratio of -1.53 and a beta of 0.83. The stock’s fifty day moving average price is $2.63 and its two-hundred day moving average price is $2.84. Allogene Therapeutics, Inc. has a one year low of $2.01 and a one year high of $5.78.

Allogene Therapeutics (NASDAQ:ALLO) last released its quarterly earnings results on Wednesday, August 7th. The company reported ($0.32) EPS for the quarter, beating the consensus estimate of ($0.35) by $0.03. Allogene Therapeutics had a negative net margin of 223,139.98% and a negative return on equity of 50.24%. On average, equities analysts anticipate that Allogene Therapeutics, Inc. will post -1.38 earnings per share for the current fiscal year.

Allogene Therapeutics Company Profile

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).